Active prophylaxis for RSV: state of art

Anna C Vittucci, Paola Zangari, Claudia Ciarlitto, Chiara Di Camillo, Annalisa Grandin, Nicola Cotugno, Maria R Marchili, Alberto Villani

Research output: Contribution to journalArticle

Abstract

Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children but represents also an important cause of morbidity in adults, particularly in the elderly and immunocompromised persons. Despite its global impact on human health, no effective treatment is available except for supportive care and no safe vaccine has been still licensed. Vaccine development has been hindered by several factors including vaccine enhanced disease associated with formalin-inactivated RSV vaccine, ethical concerns and lack of consensus concerning the most appropriate target antigen. In this review, we analyze history of RSV vaccine and current approaches for preventing RSV including live-attenuated, vector-based, subunit, nucleic acid-based, particle based vaccines and we debate about concerns on target population, correlates of protection and obstacles that are slowing the progress toward a successful RSV vaccination strategy.

Original languageEnglish
JournalMinerva Pediatrica
DOIs
Publication statusE-pub ahead of print - Oct 18 2018

Fingerprint

Respiratory Syncytial Viruses
Vaccines
Respiratory Syncytial Virus Vaccines
Inactivated Vaccines
Health Services Needs and Demand
Nucleic Acids
Formaldehyde
Vaccination
Morbidity
Antigens
Health
Therapeutics

Cite this

Vittucci, A. C., Zangari, P., Ciarlitto, C., Di Camillo, C., Grandin, A., Cotugno, N., ... Villani, A. (2018). Active prophylaxis for RSV: state of art. Minerva Pediatrica. https://doi.org/10.23736/S0026-4946.18.05305-7

Active prophylaxis for RSV : state of art. / Vittucci, Anna C; Zangari, Paola; Ciarlitto, Claudia; Di Camillo, Chiara; Grandin, Annalisa; Cotugno, Nicola; Marchili, Maria R; Villani, Alberto.

In: Minerva Pediatrica, 18.10.2018.

Research output: Contribution to journalArticle

Vittucci, AC, Zangari, P, Ciarlitto, C, Di Camillo, C, Grandin, A, Cotugno, N, Marchili, MR & Villani, A 2018, 'Active prophylaxis for RSV: state of art', Minerva Pediatrica. https://doi.org/10.23736/S0026-4946.18.05305-7
Vittucci AC, Zangari P, Ciarlitto C, Di Camillo C, Grandin A, Cotugno N et al. Active prophylaxis for RSV: state of art. Minerva Pediatrica. 2018 Oct 18. https://doi.org/10.23736/S0026-4946.18.05305-7
Vittucci, Anna C ; Zangari, Paola ; Ciarlitto, Claudia ; Di Camillo, Chiara ; Grandin, Annalisa ; Cotugno, Nicola ; Marchili, Maria R ; Villani, Alberto. / Active prophylaxis for RSV : state of art. In: Minerva Pediatrica. 2018.
@article{fe511072fa8348d78c8ffb0dc767dfdd,
title = "Active prophylaxis for RSV: state of art",
abstract = "Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children but represents also an important cause of morbidity in adults, particularly in the elderly and immunocompromised persons. Despite its global impact on human health, no effective treatment is available except for supportive care and no safe vaccine has been still licensed. Vaccine development has been hindered by several factors including vaccine enhanced disease associated with formalin-inactivated RSV vaccine, ethical concerns and lack of consensus concerning the most appropriate target antigen. In this review, we analyze history of RSV vaccine and current approaches for preventing RSV including live-attenuated, vector-based, subunit, nucleic acid-based, particle based vaccines and we debate about concerns on target population, correlates of protection and obstacles that are slowing the progress toward a successful RSV vaccination strategy.",
author = "Vittucci, {Anna C} and Paola Zangari and Claudia Ciarlitto and {Di Camillo}, Chiara and Annalisa Grandin and Nicola Cotugno and Marchili, {Maria R} and Alberto Villani",
year = "2018",
month = "10",
day = "18",
doi = "10.23736/S0026-4946.18.05305-7",
language = "English",
journal = "Minerva Pediatrica",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",

}

TY - JOUR

T1 - Active prophylaxis for RSV

T2 - state of art

AU - Vittucci, Anna C

AU - Zangari, Paola

AU - Ciarlitto, Claudia

AU - Di Camillo, Chiara

AU - Grandin, Annalisa

AU - Cotugno, Nicola

AU - Marchili, Maria R

AU - Villani, Alberto

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children but represents also an important cause of morbidity in adults, particularly in the elderly and immunocompromised persons. Despite its global impact on human health, no effective treatment is available except for supportive care and no safe vaccine has been still licensed. Vaccine development has been hindered by several factors including vaccine enhanced disease associated with formalin-inactivated RSV vaccine, ethical concerns and lack of consensus concerning the most appropriate target antigen. In this review, we analyze history of RSV vaccine and current approaches for preventing RSV including live-attenuated, vector-based, subunit, nucleic acid-based, particle based vaccines and we debate about concerns on target population, correlates of protection and obstacles that are slowing the progress toward a successful RSV vaccination strategy.

AB - Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children but represents also an important cause of morbidity in adults, particularly in the elderly and immunocompromised persons. Despite its global impact on human health, no effective treatment is available except for supportive care and no safe vaccine has been still licensed. Vaccine development has been hindered by several factors including vaccine enhanced disease associated with formalin-inactivated RSV vaccine, ethical concerns and lack of consensus concerning the most appropriate target antigen. In this review, we analyze history of RSV vaccine and current approaches for preventing RSV including live-attenuated, vector-based, subunit, nucleic acid-based, particle based vaccines and we debate about concerns on target population, correlates of protection and obstacles that are slowing the progress toward a successful RSV vaccination strategy.

U2 - 10.23736/S0026-4946.18.05305-7

DO - 10.23736/S0026-4946.18.05305-7

M3 - Article

C2 - 30334621

JO - Minerva Pediatrica

JF - Minerva Pediatrica

SN - 0026-4946

ER -